Abstract
Lichen planus pigmentosum (LPP) is an uncommon variant of Lichen plan clinically characterized by lichenoid lesions of photoexposed. Pruritus may be present in the early active phase, and the disease often has a prolonged clinical course [1]. There is no effective treatment for LPP. Various therapeutic modalities such as topical tacrolimus, topical and systemic corticosteroids, high-dose vitamin A and lasers have been tried with no prometting results [2-6]. Isotretinoin is a first generation retinoid discovered in 1952 and was approved by the FDA for the treatment of nodulokystic acne in 1982. Isotretinoin anti-inflammatory properties have allowed it to be used in disorders other than acne. Its adverse effects range from simple xerosis to teratogenicity. There have been a few isolated reports of isotretinoin (topical/systemic) efficiency in the treatment of LPP but its role in LPP has not yet been totally elucidated [7,8]. The objective of this study was to evaluate the efficiency and safety of low-dose isotretinoin in the treatment of LPP
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
